Fixing common blood disorder would make kidney transplants more successful

Anemia commonly arises in patients with kidney disease because the kidneys secrete most of the hormone erythropoietin that stimulates red blood cell production. Anemia is also a common complication of kidney transplantation, with a prevalence of 25% to 40% after the first year.

Gabriel Choukroun, MD, PhD (CHU Amiens in France) and his colleagues initiated the Correction of Anemia and PRogression of Renal Insufficiency in Transplant patients (CAPRIT) study to see if the drug epoetin beta (a synthetic form of erythropoietin) could help preserve kidney function in kidney transplant recipients with anemia. Specifically, the investigators tested whether completely correcting anemia (by normalizing levels of hemoglobin, a blood component that carries oxygen) is better than partially correcting anemia.

During the study, 63 kidney transplant recipients took epoetin beta so that their hemoglobin levels remained in the normal range of 13.0 to 15.0 g/dL, while 62 patients took epoetin beta so that their hemoglobin levels hovered at a lower concentration of 10.5 to 11.5 g/dL.

Among the major findings after patients were treated for two years:

• 4.8% of patients with completely corrected anemia developed kidney failure, compared with 21% of patients with partially corrected anemia.
• 94.6% of transplanted kidneys in patients with completely corrected anemia were functional, compared with 80% in patients with partially corrected anemia.
• Patients with completely corrected anemia experienced a significant improvement in quality of life at six and 12 months after starting therapy.

More information: The article, entitled "Correction of Post-Kidney Transplant Anemia Reduces Progression of Allograft Nephropathy," will appear online on December 22, 2011, doi: 10.1681/ASN.2011060546

Provided by American Society of Nephrology